Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myo
about
The antioxidant paradox: less paradoxical now?Current therapies for lowering lipoprotein (a)Understanding the role of B cells in atherosclerosis: potential clinical implicationsGeneration and biological activities of oxidized phospholipidsSimvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering EffectB-cell aortic homing and atheroprotection depend on Id3.B cell subsets in atherosclerosis.Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseasesModified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate dietHigh plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids.Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trialOxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.A simplified procedure for semi-targeted lipidomic analysis of oxidized phosphatidylcholines induced by UVA irradiation.Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases.2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in AtherosclerosisThe association between oxidized low-density lipoprotein antibodies and hematological diseases.Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population studyOxidative stress as a mediator of cardiovascular disease.Cardiovascular Complications in CKD Patients: Role of Oxidative Stress.Role of phospholipid oxidation products in atherosclerosis.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.The variability of oxLDL-induced cytotoxicity on different types of cell lines.Lipoprotein(a): A missing culprit in the management of athero-thrombosis?Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels.HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease.
P2860
Q24618841-DFC645D6-5717-4F0A-9879-F6BBC7CFC6B5Q26830297-1F80EE8E-CE42-4B3F-ADEC-4E5AC65A8171Q26991813-1326FB97-7CA8-45BA-B805-CB1DA8011641Q28389691-2E6C65D3-1E5F-4CFB-A2D6-53ECB540B662Q28553042-44AD8E86-9BDD-42B1-8778-0357419A06EEQ30422974-C3BFD553-9321-49C5-8032-F31C804B8304Q30423324-9DFE440C-63A1-41E3-817B-FAB749B671D1Q33633974-A15DE46C-0E55-4903-AA40-AF0C81C1B074Q34072528-40FEC186-4A90-4B7C-A56B-997237FFAB88Q34188087-C49709D0-4085-4AD5-B23A-C81500B9D625Q35138355-30A04126-0286-4886-AABC-57FA6AF5B4B3Q35212898-10C288BE-533D-4B6A-9713-CD4A9CF7632DQ35276226-2CE99563-718F-4027-9048-FAEE6674FEF3Q35592510-01EC2FA6-8B73-4A3F-9046-1050C794230BQ35958509-F028EAEA-C22C-4CB7-8950-60261B260EE3Q36817578-AC96B7B4-347B-4624-A351-30057E530BCCQ37146276-98A2768B-1956-4ABD-9E67-B061841AD89CQ37403038-2A267B05-F8A4-408E-9ED1-A44C626A05B3Q37660722-6EECD143-4503-4241-84C5-855818A0E91EQ37780644-3017ACB4-BCE6-4C5F-B676-B0E959A2E538Q37831154-E04BBA24-349D-4F35-9F06-552851D6DF89Q38039282-C1E4FEF8-C4EF-4EC6-9872-AE1C1BF48DDFQ38299279-A2A76D15-8884-4DD8-9508-49EC6DBADF85Q38825512-A938B312-AC95-473A-8B6E-AC84AF55C077Q38846881-636E929F-F388-472A-AD58-B49CE786F4C7Q39182530-4E88C582-8DBC-4685-9BE8-9EF09EFA1AFFQ39368804-3376F4B4-3F9B-4124-BDAD-B4ED571ADB93Q42357350-EB54E8D4-8A10-4E4A-A390-3A68B5DCB72BQ42408461-B7E59BF3-A188-4BA6-A371-9DCFCA686271Q51032319-B996E025-ABAC-4A99-A272-48F283CCCB0C
P2860
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myo
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@en
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@nl
type
label
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@en
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@nl
prefLabel
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@en
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@nl
P2093
P50
P921
P1476
Relationship of oxidized phosp ...... : Results from the MIRACL (Myo
@en
P2093
Alexander E Fraley
Anders G Olsson
Gregory G Schwartz
MIRACL Study Investigators
Michael Szarek
Peter Ganz
Scott Kinlay
P304
P356
10.1016/J.JACC.2009.02.041
P407
P577
2009-06-01T00:00:00Z